Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORE-001 in Underweight Elderly Participants
2024-516958-22-00Phase 2Authorised
- Sponsor
- Orexa
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lidocaine in Underweight (2 arms), sponsored by Orexa. Primary endpoints: Change from baseline in the weight of food intake of a standardized lunch on treatment day 1 and Change from baseline in the weight of food intake of a standardized lunch on treatment day 42. Planned start Feb 2025; status: authorised.
02
Drugs
lidocaine
03
Conditions
Underweight
Beyond the preview
Go deeper on 2024-516958-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516958-22-00.